Osthole enhances the immunosuppressive effects of bone marrow‐derived mesenchymal stem cells by promoting the Fas/FasL system

• DOI: 10.1111/jcmm.16459
• Publication Date: 2021-03-22T02:24:06Z
• Authors: Yang Yu; Meng Chen; Shiyao Yang; Bingyi Shao; Liang Chen; Lei Dou; Jing Gao; Deqin Yang
• Keywords: Fas ligand; Cell therapy

Thanks to the advantages of easy harvesting and escape from immune rejection, autologous bone marrow-derived mesenchymal stem cells (BMSCs) are promising candidates for immunosuppressive therapy against inflammation autoimmune diseases. However, is still challenging because immunomodulatory properties BMSCs always impaired by immunopathogenesis in patients. Because its reliable extensive biological activities, osthole has received increased clinical attention. In this study, we found that derived osteoporosis donors were ineffective cell experimental inflammatory colitis osteoporosis. vivo vitro tests showed down-regulation Fas FasL expression, ability osteoporotic induce T-cell apoptosis decreased. Through application osthole, successfully restored improved their treatment efficacy addition, enhanced after pre-treatment. our data highlight a new approach pharmacological modification (ie osthole) improve regulatory performance healthy or microenvironment. The development targeted strategies enhance using may be significantly these findings.